Ann: NASH clinical trial presentation & continued revenue growth, page-10

Hairy Richard, What you said is not correct.

The presentation entitled “IMM-124E Improves Metabolic Endotoxemia and Markers of Liver Injuryin Non-Alcoholic Steatohepatitis” will be on the 11th of November 2018 at the Novel Therapeuticsfor NASH session. A copy of the presentation will be made available on Immuron’s website atwww.immuron.com.Travelan was on display at HealthEd, the Australian General Practitioner conference series, inSydney, Melbourne and Brisbane. At these events, Dr. Bernie Hudson, a respected key opinionleader in Travel Medicine, presented the latest research on travellers’ diarrhoea to an audience ofover 2,000 medical professionals. 

The 2000 medical professionals attended the Sydney,Melbourne and Brisbane conference.  They have not given an indication of the audience to Aran Sanyul Conference to be held in San Francisco with regard to IMM-124E.

I think people need to look at the "Big Picture".

Dr Bernie Hudson.  Who is he?

Professor Arun Sanyal

World renowned in his field of expertise with NASH.